Peter Rossing, DMSc, MD
Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Matthew R. Weir, MD
New Insights into the Management of CKD in T2D: The Role of MRA Therapies
Robert J. Chilton, DO
John R. Nelson, MD, FACC, FNLA, FASNC
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
Michael Miller, MD, FACC, FAHA, FNLA
Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC
Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA
Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid…
